{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:52:15Z","timestamp":1762098735272,"version":"3.34.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pcad.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:19:30Z","timestamp":1716304770000},"page":"86-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Predictors of short-term and long-term effects of mavacamten in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"86","author":[{"given":"Kaitlin M.","family":"Roehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Maria","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Suppah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pcad.2024.05.008_bb0005","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center","volume":"S0033-0620","author":"Desai","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.pcad.2024.05.008_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.pcad.2024.05.008_bb0015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2024.05.008_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pcad.2023.08.006","article-title":"Medical therapies for hypertrophic cardiomyopathy: current state of the art","volume":"80","author":"Desai","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.05.008_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pcad.2023.08.002","article-title":"The evolving paradigm and current perception of hypertrophic cardiomyopathy: implications for management","volume":"80","author":"Del Franco","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2024.05.008_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcad.2023.08.001","article-title":"Unmet needs and future directions in hypertrophic cardiomyopathy","volume":"80","author":"Kaur","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.pcad.2024.05.008_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.mayocp.2023.11.019","article-title":"Genotype influences mavacamten responsiveness in obstructive hypertrophic cardiomyopathy","volume":"99","author":"Giudicessi","year":"2024","journal-title":"Mayo Clin Proc"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:02:35Z","timestamp":1738188155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":7,"alternative-id":["S0033062024000768"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.05.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of short-term and long-term effects of mavacamten in obstructive hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}